The KEAP1 Knockout CAL-27 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of CAL-27 oral squamous cell carcinoma cells bearing a loss-of-function disruption at the KEAP1 locus. This heterogeneous pool enables unbiased functional interrogation of KEAP1-dependent pathways without clonal selection biases, serving as a versatile tool for studying NRF2 regulation, redox homeostasis, and proteasomal degradation in head and neck cancer.
CAL-27 is a human tongue squamous cell carcinoma line widely used to model oral cavity malignancies. It maintains epithelial tumor features and is employed to investigate oncogenic signaling, metabolic adaptations, and therapeutic susceptibilities. The KEAP1 knockout in this background allows analysis of how NRF2 pathway dysregulation influences tumor cell behavior, oxidative stress resistance, and drug responses.
KEAP1 acts as a substrate adaptor for the CUL3?CRBX1 E3 ubiquitin ligase, constitutively targeting NRF2 for ubiquitination and proteasomal degradation. Basally, KEAP1-mediated ubiquitination keeps NRF2 levels low. Oxidative stress or electrophilic compounds modify KEAP1 cysteine residues, releasing NRF2 for nuclear translocation and activation of ARE-driven cytoprotective genes, including HMOX1, NQO1, GCLC, and TXNRD1. The autophagy adaptor p62/SQSTM1 can also sequester KEAP1, modulating NRF2 stability.
In head and neck squamous cell carcinoma, KEAP1 inactivation and NRF2 hyperactivation promote antioxidant capacity, metabolic reprogramming, and chemoradioresistance. This knockout model directly addresses constitutive NRF2 signaling consequences in oral cancer, with relevance to lung adenocarcinoma and hepatocellular carcinoma where KEAP1?CNRF2 alterations drive aggressiveness.
Typical applications include redox homeostasis, drug resistance, and metabolic studies using western blotting for NRF2 and targets (HMOX1, NQO1, TXNRD1), RT-qPCR for ARE-driven transcripts, ARE-luciferase reporter assays, and NRF2 immunofluorescence. Cell viability under oxidative stress confirms pathway function. The polyclonal format suits population-level screens and mechanistic analyses. For technical inquiries, contact Ascent Research.
